Home Cd software Advanced Proteome Therapeutics Announces Appointment of Mr. Cory Brandolini to the Board of Directors

Advanced Proteome Therapeutics Announces Appointment of Mr. Cory Brandolini to the Board of Directors

0

The MarketWatch News service was not involved in the creation of this content.

Vancouver, British Columbia, Nov. 21, 2022 (Newsfile Corp via COMTEX) — Vancouver, British Columbia–(Newsfile Corp. – Nov. 21, 2022) – Advanced Proteome Therapeutic Society (TSXV: APC) (FSE: 0E8) (“APC” or the “Company”) is pleased to announce that it has appointed Mr. Cory Brandolini to the Board of Directors.

Mr. Brandolini has over 3 decades of experience in capital markets and as an advisor to high-growth, disruptive software companies across numerous technology industry verticals. During his career, he has helped raise hundreds of millions of dollars for public and private companies specifically in the technology sector. Mr. Brandolini’s experience includes two decades in the investment industry.

Mr. Brandolini was the Founder, CEO and President of RESAAS Services Inc., an award-winning global real estate cloud platform. Under his leadership, RESAAS experienced its greatest phase of growth, growing from a raw start to over 400,000 subscribed real estate agents worldwide, including the biggest brands in real estate. Mr. Brandolini made RESAAS one of the first true IPOs on the Canadian Stock Exchange and helped the company raise over $30 million in investment. Most recently, Mr. Brandolini is the co-founder, president and CEO of Railtown AI Technologies Inc., developers of a SAAS solution for software development teams that uses AI to drive optimizations and provide insights to every stage of software development. Railtown converts CI/CD systems into complete CI/CD/CM (continuous monitoring) systems – monitor, diagnose and prioritize faults across the entire CI/CD environment on a single platform. Railtown’s continuous machine learning application will enable developers to accelerate innovation while ensuring the reliability and increased speed of their applications. In addition, he continued to provide capital markets and M&A advisory services to technology companies, including Teleo (VoIP platform acquired by Microsoft), WISR (Artificial Intelligence Incubator), AuthenTicket (Ticket Verification Technology).

Paul Woodward, CEO of the company, said, “We are delighted to have Cory join the board; he is a seasoned entrepreneur and investor with extensive experience in technology and financial markets. I have known Cory for many years and look forward to his contributions to the APC.”

ABOUT THE COMPANY:
Advanced Proteome Therapeutics Corporation, through its subsidiary, Advanced Proteome Therapeutics Inc., has invented a proprietary protein conjugation technology that enables the development of superior antibody-drug conjugates through improved site-specific labeling, control of drug-antibody ratio and activation of combined payloads. The technology has compelling preclinical data demonstrating improved homogeneity and increased in vivo potency compared to current state-of-the-art binding technology. The company believes the technology will enable the development of safer and more potent antibody-drug conjugate therapies and is seeking licensing and partnership opportunities to advance development and create shareholder value.

FOR MORE INFORMATION, PLEASE CONTACT:
Advanced Proteome Therapeutic Society
Paul Woodward
President and CEO
Tel: 604 690-3797
http://www.advancedproteome.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This press release contains forward-looking statements relating to the Company’s future operations and other statements that are not historical facts. Forward-looking statements are often identified by words such as “will”, “may”, “should”, “intend”, “anticipate”, “expect” and similar expressions. All statements other than statements of historical facts included in this release, including, without limitation, statements regarding the Company’s future plans and objectives, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations are the risks detailed from time to time in the Company’s filings with securities regulatory authorities.

Readers are cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those anticipated due to numerous known and unknown risks, uncertainties and other factors, many of which are beyond the Company’s control. Accordingly, the Company cannot guarantee that any forward-looking statements will materialize, and readers should not place undue reliance on forward-looking information. Such information, although considered reasonable by management at the time it was prepared, may prove to be incorrect and actual results may differ materially from those anticipated. The forward-looking statements contained in this press release are expressly qualified by this cautionary statement. The forward-looking statements contained in this press release are made as of the date of this press release and the Company will not publicly update or revise any of the forward-looking statements included except as expressly required by Canadian securities law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/145204

COMTEX_419438082/2523/2022-11-21T19:40:48

Is there a problem with this press release? Contact the Comtex source provider at [email protected] You can also contact MarketWatch customer service through our Customer Center.

copyright (c) newsfile corp. 2022. all rights reserved

The MarketWatch News service was not involved in the creation of this content.